AUTHOR INDEX

ABDULLA, A. *see* MILTON, J.C.
ÁCS, N. *see* BÁNHIDY, F.
ADAMSKA, K. *see* WYKRETOWICZ, A.
AIRAKSINEN, M.S. *see* BELL, J.S.
AKHTAR, S. *see* MISHRA, B.
AKHTAR, S. *see* SAHOO, S.
ALAMARTINE, E. *see* BERGES, A.
ALCELIK, A. *see* CINEMRE, H.
ANDERSSON, T. *see* SOSTEK, M.B.
ANTIGNAC, M., BARROU, B., FARINOTTI, R., LECHAT, P. & URIEN, S. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients: 750
ARIMONE, Y., MIREMONT-SALAMÉ, G., HARAMBURU, F., MOLIMARD, M., MOORE, N., FOURRIER-RÉGLAT, A. & BÉGAUD, B. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions: 482
ARONSON, J.K. An agenda for research on adverse drug reactions: 119
ARONSON, J.K. Old drugs – new uses: 563
ARONSON, J.K. Plagiarism – please don't copy: 403
ARONSON, J.K. Time to abandon the term 'patient concordance': 711
ARONSON, J.K., COHEN, A., RITTER, J.M., BEGG, E.J., LEWIS, L.D. & CHACHTER, M.S. Editors' Report for 2006: 253
ASARI, A., ILES-SMITH, H., CHEN, Y.-C., NADERER, O.J., JOHNSON, M.A., YUEN, G.J., OTTO, V., DUNN, J.A. & GOKAL, R. Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure: 738
ASLANI, P. *see* BELL, J.S.
ASLANI, P. *see* MAI, A.
ATTHOBARI, J., GANSEVOORT, R.T., VISSER, S.T., DE JONG, P.E. & DE JONG-VAN DEN BERG, L.T.W. The effect of screening for cardio-renal risk factors on drug use in the general population: 810

BACKMAN, J.T. *see* FANTA, S.
BAE, K.S. *see* KANG, S.H.
BANFIELD, C. *see* GUPTA, S.K.
BANGS, M.E. *see* CUI, Y.M.
BÁNHIDY, F., ÁCS, N., PUHÓ, E. & CZEIZEL, A.E. Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth: 510
BARROU, B. *see* ANTIGNAC, M.
BATEMAN1, D.N. *see* PAKRAVAN, N.
BAUMAN, J.N. *see* PETERKIN, V.C.
BAUMANN, A. *see* MOULD, D.R.
BECKWITH, S. FRANKLIN, P. & LEATHARD, H. Oxford Handbook of Nurse Prescribing: 115
BÉGAUD, B. *see* ARIMONE, Y.
BEGG, E.J. *see* ARONSON, J.K.
BEIJNEN, J.H. *see* JOERGER, M.
BELL, J.S., AIRAKSINEN, M.S., LYLES, A., CHEN, T.F. & ASLANI, P. Concordance is not synonymous with compliance or adherence: 710
BELOEIL, H., EURIN, M., THÉVENIN, A., BENHAMOU, D. & MAZOIT, J.-X. Effective dose of nefopam in 80% of patients (ED_{80}): a study using the continual reassessment method: 686
BENETON, M., CHAPET, S., BLASCO, H., GIRAUDEAU, B., BOISDRON-CELLE, M., DEPORTE-FETY, R., DENIS, F., NARCISSO, B., CALAIS, G. & LE GUELLEC, C. Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy: 613
BENHAMOU, D. *see* BELOEIL, H.
BENNETT, K. *see* KABIR, Z.
BENNETT, K. *see* MAHMUD, A.
BENNETT, K. *see* OKECHUKWU, I.
BENNETT, K. *see* TEELING, M.
BÉRARD, A. *see* OFORI, B.
BERGES, A., LAPORTE, S., EPINAT, M., ZUFFEREY, P., ALAMARTINE, E., TRANCHAND, B., DECOUSUS, H., & MISMETTI, P. Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old: 428
BERKOVITCH, M. *see* GOLDSTEIN, L.H.
BERLIN, R.G. *see* DESJARDINS, P.J.
BINIAURISHVILI, B.Z. *see* GOLDSTEIN, L.H.
BIOLLAZ, J. *see* TSCHUPPERT, Y.
BIRKETT, D.J. *see* ELLIOT, D.J.
BISGAARD, H. *see* BØNNELYKKE, K.
BLANCHE, S. *see* JULLIEN, V.
BLASCO, H. *see* BENETON, M.
BOCKARIE, M.J. *see* MEHLOTRA, R.K.
BOISDRON-CELLE, M. *see* BENETON, M.
BONATE, P.L. *see* MOULD, D.R.
BONGARD, V. *see* DURRIEU, G.
BØNNELYKKE, K., JESPERSEN, J.J. & BISGAARD, H. Age dependent systemic exposure to inhaled salbutamol: 241
BONOVAS, S., FILIOUSSI, K., TSANTES, A. & SITARAS, N.M. Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies: 255
BOUILLON-PICHAULT, M. *see* JULLIEN, V.
BOURAOUI, K. *see* HMOUDA, H.
BOURAOUI, K. *see* SALEM, C.B.
BOURGAREL-REY, V. *see* SOLAS, C.
BOUW, M.R. *see* PESCOVITZ, M.D.
BOZKURT, S. *see* UNVERIR, P.
BRADSHAW, C.M. *see* SAMUELS, E.R.
BRAMNESS, J.G., FURU, K., ENGELAND, A. & SKURTVEIT, S. Carisoprodol use and abuse in Norway. A pharmacoepidemiological study: 210
BRAUNSTEIN, R. *see* GOLDSTEIN, L.H.
BRENDEL, K. *see* DARTOIS, C.
BRETTMAN, L.R. *see* MOULD, D.R.
BRUN, A. *see* THUNELL, S.
BRUNET, C. *see* SOLAS, C.
BUCLIN, T. *see* TSCHUPPERT, Y.
BÜHRMANN, S. *see* STASS, H.
BURGGRAAF, J. *see* VAN DER VORST, M.M.J.

CAI, Z.-J. *see* TANG, Y.-L.
CALAIS, G. *see* BENETON, M.
CALLEJA, E. *see* PESCOVITZ, M.D.
CALS, L. *see* MAGNÉ, N.
CALVO, L. *see* MORENO, R.
CENACCHI, V. *see* CIVELLI, M.
CHACHTER, M.S. *see* ARONSON, J.K.
CHAPET, S. *see* BENETON, M.
CHAPPUY, H. *see* HIRT, D.
CHEN, B.-L. *see* ZHANG, W.
CHEN, Q. *see* TANG, Y.-L.
CHEN, T.F. *see* BELL, J.S.
CHEN, W. *see* PEREZ-RUIXO, J.J.
CHEN, X. *see* ZHANG, Y.
CHEN, Y. *see* SOSTEK, M.B.
CHEN, Y.-C. *see* ASARI, A.
CHOI, J.H., LEE, Y.J., JANG, S.B., LEE, J.-E., KIM, K.H. & PARK, K. Influence of the *CYP3A5* and *MDR1* genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects: 185
CHOW, A. *see* PEREZ-RUIXO, J.J.
CHURCH, R., TANSEY, T., & COHEN, A. Burroughs Wellcome & Co. Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry, 1880–1940: 562
CINEMRE, H., KORKMAZ, U., ALCELIK, A., ONDER, E. & GUNGOR, A. Safety of amlodipine use in patients with acute intermittent porphyria: 246
CIVELLI, M., PRETI, A.P.M., CENACCHI, V., RONDELLI, I., GUASTALLA, D., TARRAL, A., DOSTERT, P., GUILLEVIC, Y. & HOMERY, M.-C. Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF

© 2007 Blackwell Publishing Ltd

4227, in healthy postmenopausal women: 304
COHEN, A. *see* ARONSON, J.K.
COHEN, A. *see* CHURCH, R.
COHEN, A. Should we tolerate tolerability as an objective in early drug development?: 249
COHEN, A.F. *see* VAN DER VORST, M.M.J.
COMETS, E. *see* DARTOIS, C.
CONIL, J.M., GEORGES, B., LAVIT, M., LAGUERRE, J., SAMII, K., HOUIN, G. & SAIVIN, S. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation: 27
COYNE, T. *see* DHAUN, N.
CUI, Y.M., TENG, C.H., PAN, A.X., YUEN, E., YEO, K.P., ZHOU, Y., ZHAO, X., LONG, A.J., BANGS, M.E. & WISE, S.D. Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele: 445
CULLEN, G. *see* DONNELLAN, F.
CUTLER, D.L. *see* GUPTA, S.K.
CZEIZEL, A.E. *see* BÁNHIDY, F.

DAILLY, E. *see* VICTORRI-VIGNEAU, C.
DAMASE-MICHEL, C. *see* DURRIEU, G.
DARLINGTON, L.G. *see* FORREST, C.M.
DARTOIS, C., BRENDEL, K., COMETS, E., LAFFONT, C.M., LAVEILLE, C., TRANCHAND, B., MENTRÉ, F., LEMENUEL-DIOT, A. & GIRARD, P. Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey: 603
DASCALU, A. *see* SIEVENPIPER, J.L.
DE BOER, A. *see* GUMBS, P.D.
DE BOER, A. *see* SCHELLEMAN, H.
DE DONCKER, P. *see* HOETELMANS, R.M.W.
DE GRAEFF, A. *see* JOERGER, M.
DE GROOT, M.C.H. & VAN PUIJENBROEK, E.P. Clindamycin and taste disorders: 542
DE GROOT, M.C.H. *see* HÄRMARK, L.
DE HOON, J.N. *see* VAN DER SCHUEREN, B.J.
DE JONG, P.E. *see* ATTHOBARI, J.
DE JONG-VAN DEN BERG, L.T.W. *see* ATTHOBARI, J.
DE LEPELEIRE, I. *see* VAN DER SCHUEREN, B.J.
DE PAUW, M. *see* HOETELMANS, R.M.W.
DE WIT, G.A. *see* GUMBS, P.D.
DEAR, J.W. & WEBB, D.J. Disease mongering – a challenge for everyone involved in healthcare: 122
DECOSTERD, L.A. *see* TSCHUPPERT, Y.
DECOUSUS, H. *see* BERGES, A.
DEJONGSTE, M.J.L. *see* DOBRE, D.
DELAUGERRE, C. *see* JULLIEN, V.
DEN HARTIGH, J. *see* VAN DER VORST, M.M.J.
DENG, S. *see* ZHANG, W.
DENIS, F. *see* BENETON, M.
DEPORTE-FETY, R. *see* BENETON, M.
DEPRE, M. *see* VAN DER SCHUEREN, B.J.
DESJARDINS, P.J. & BERLIN, R.G. Efficacy of phenylephrine: 555
DHAUN, N., MELVILLE, V., KRAMER, W., STAVROS, F., COYNE, T., SWAN, S., GODDARD, J. & WEBB, D.J. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment: 733
DICKINSON, G.L., LENNARD, M.S., TUCKER, G.T. & ROSTAMI-HODJEGAN, A. The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies – *CYP2C9* and warfarin as an example: 14
DIMET, J. *see* JULLIEN, V.
DOBRE, D., VAN VELDHUISEN, D.J., DEJONGSTE, M.J.L., VAN SONDEREN, E., KLUNGEL, O.H., SANDERMAN, R., RANCHOR, A.V. & HAAIJER-RUSKAMP, F.M. The contribution of observational studies to the knowledge of drug effectiveness in heart failure: 406
DOESSEGGER, L. *see* THAKRAR, B.T.
DONNELLAN, F., CULLEN, G., HEGARTY, J.E. & MCCORMICK, P.A. Ischaemic complications of Glypressin in liver disease: a case series: 550
DOSTERT, P. *see* CIVELLI, M.
DRAGONI, S. *see* GORI, T.
DREWE1, J. *see* HAEGELI, L.
DROGOUL, M.-P. *see* SOLAS, C.
DRUMMOND, P.D. Repeated cycles of electrical stimulation decrease vasoconstriction and axon-reflex vasodilation to noradrenaline in the human forearm: 421
DUNN, J.A. *see* ASARI, A.
DURAND, A. *see* SOLAS, C.
DURRIEU, G., HURAULT, C., BONGARD, V., DAMASE-MICHEL, C. & MONTASTRUC, J.L. Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course: 233

EARL, J.W. *see* NATH, C.E.
ECCLES, R. Efficacy of phenylephrine: 557
ELIAS, M. *see* GOLDSTEIN, L.H.
ELLIOT, D.J., SUHARJONO, LEWIS, B.C., GILLAM, E.M.J., BIRKETT, D.J., GROSS, A.S. & MINERS, J.O. Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination: 450
ELLIOTT, K. *see* STEWART, D.
ENGELAND, A. *see* BRAMNESS, J.G.
EPINAT, M. *see* BERGES, A.
ERNST, E. A re-evaluation of kava (*Piper methysticum*): 415
ESPOSITO-FESTEN, J.E., ZANEN, P., TIDDENS, H.A.W.M. & LAMMERS, J.-W.J. Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size: 328
ETIENNE-GRIMALDI, M.-C. *see* MAGNÉ, N.
EURIN, M. *see* BELOEIL, H.
EVANS, A.M. *see* FORNASINI, G.
EZATAGHA, A. *see* SIEVENPIPER, J.L.

FAN, L. *see* ZHANG, W.
FANTA, S., JÖNSSON, S., BACKMAN, J.T., KARLSSON, M.O. & HOPPU, K. Developmental pharmacokinetics of ciclosporin – a population pharmacokinetic study in paediatric renal transplant candidates: 772
FARDON, T.C. *see* TAYAB, Z.R.
FARINOTTI, R. *see* ANTIGNAC, M.
FAVA, S. *see* FRENDO, M.
FEELY, J. *see* KABIR, Z.
FEELY, J. *see* MAHMUD, A.
FEELY, J. *see* OKECHUKWU, I.
FEELY, J. *see* TEELING, M.
FERNANDEZ, C. *see* MORENO, R.
FILIOUSSI, K. *see* BONOVAS, S.
FIRTION, G. *see* HIRT, D.
FISHER, P. *see* MATHIE, R.T.
FORCONI, S. *see* GORI, T.
FORMENTO, J.-L. *see* MAGNÉ, N.
FORNASINI, G., UPTON, R.N. & EVANS, A.M. A pharmacokinetic model for L-carnitine in patients receiving haemodialysis: 335
FORREST, C.M., MACKAY, G.M., STOY, N., STONE, T.W. & DARLINGTON, L.G. Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin: 517
FORST, T., SMITH, T., SCHÜTTE, K., MARCUS, P. & PFÜTZNER, A. Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain: 75
FOURRIER-RÉGLAT, A. *see* ARIMONE, Y.
FRANCOUAL, M. *see* MAGNÉ, N.
FRANKLIN, P. *see* BECKWITH, S.
FRENDO, M., THEUMA, R. & FAVA, S. Delayed bezafibrate-induced angio-oedema in a 68-year-old man: 560
FRIXON-MARIN, V. *see* SOLAS, C.
FURU, K. *see* BRAMNESS, J.G.
FURU, K. *see* SAKSHAUG, S.

GALEOTE, G. *see* MORENO, R.
GALLEYRAND, J. *see* TSCHUPPERT, Y.
GANSEVOORT, R.T. *see* ATTHOBARI, J.
GANSSER, D. *see* STANGIER, J.
GASTAUT, J.-A. *see* SOLAS, C.
GAUD, C. *see* TSCHUPPERT, Y.
GEORGES, B. *see* CONIL, J.M.
GIBBINS, J.M. *see* GUERRERO, J.A.
GILBERT, A.L. *see* ROUGHEAD, E.E.
GILLAM, E.M.J. *see* ELLIOT, D.J.
GIRARD, P. *see* DARTOIS, C.
GIRAUDEAU, B. *see* BENETON, M.
GODDARD, J. *see* DHAUN, N.
GODDARD, J. *see* PAKRAVAN, N.
GOKAL, R. *see* ASARI, A.
GOLDSTEIN, L.H., ELIAS, M., RON-AVRAHAM, G., BINIAURISHVILI, B.Z., MADJAR, M., KAMARGASH, I., BRAUNSTEIN, R., BERKOVITCH, M. & GOLIK, A. Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards: 373
GOLIK, A. *see* GOLDSTEIN, L.H.
GOOSEN, T.C. *see* PETERKIN, V.C.
GORI, T., STOLFO, G.D., SICURO, S., DRAGONI, S., LISI, M., FORCONI, S. & PARKER, J.D. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight: 145
GRAHNÉN, A. *see* KARLSSON, K.E.
GRAHNÉN, A. *see* LÖNNEBO, A.
GRIRA, M. *see* HMOUDA, H.
GROSS, A.S. *see* ELLIOT, D.J.
GRUNDSCHOBER, S.B. *see* THAKRAR, B.T.
GUASTALLA, D. *see* CIVELLI, M.
GUERRERO, J.A., NAVARRO-NUÑEZ, L., LOZANO, M.L., MARTÍNEZ, C., VICENTE, V., GIBBINS, J.M. & RIVERA, J. Flavonoids inhibit the platelet TxA2 signalling pathway and antagonize TxA2 receptors (TP) in platelets and smooth muscle cells: 133
GUILLEVIC, Y. *see* CIVELLI, M.
GUMBS, P.D., VERSCHUREN, W.M.M., SOUVEREIN, P.C., MANTEL-TEEUWISSE, A.K., DE WIT, G.A., DE BOER, A. & KLUNGEL, O.H. Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution: 680
GUNALE, B.K. *see* SUBBANNA, P.K.
GUNGOR, A. *see* CINEMRE, H.
GUO, Y. *see* ZHANG, Y.
GUPTA, S.K., KANTESARIA, B., BANFIELD, C. & WANG, Z. Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults: 174
GUPTA, S.K., SWAN, S.K., MARBURY, T., SMITH, W., SCHWARTZ, S., KOLZ, K. & CUTLER, D.L. Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency: 726
GUZIK, P. *see* WYKRETOWICZ, A.

HAAIJER-RUSKAMP, F.M. *see* DOBRE, D.
HAEGELI, L., ROCCA, H.P.B.-L., WENK, M., PFISTERER, M., DREWE1, J. & KRÄHENBÜHL, S. Sublingual administration of furosemide: new application of an old drug: 804
HAGGART, K. *see* TAYAB, Z.R.
HARAMBURU, F. *see* ARIMONE, Y.
HÄRMARK, L., VAN DER WIEL, H.E., DE GROOT, M.C.H. & VAN GROOTHEEST, A.C. Proton pump inhibitor-induced acute interstitial nephritis: 819
HARRISON, T.W. *see* MORTIMER, K.J.
HART, M. *see* PESCOVITZ, M.D.
HAYES, S. *see* PEREZ-RUIXO, J.J.
HE, Y.-J. *see* ZHANG, W.
HEGARTY, J.E. *see* DONNELLAN, F.
HELMS, P.J. *see* STEWART, D.
HENDERSON, L. *see* RICHARDSON, W.N.
HILL, A. *see* HOETELMANS, R.M.W.
HILLMEN, P. *see* MOULD, D.R.
HIRT, D., URIEN, S., JULLIEN, V., FIRTION, G., CHAPPUY, H., REY, E., PONS, G., MANDELBROT, L. & TRELUYER, J.-M. Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples: 634
HMOUDA, H. *see* SALEM, C.B.
HMOUDA, H., SALEM, C.B., GRIRA, M., SLIM, R. & BOURAOUI, K. Carbamazepine-induced urinary retention: 833
HOCHHAUS, G. *see* MORTIMER, K.J.
HOCHHAUS, G. *see* TAYAB, Z.R.
HOELEN, D.W.M., TJAN, D.H.T., VAN VUGT, R., VAN DER MEER, Y.G. & VAN ZANTEN, A.R.H. Severe local vancomycin induced skin necrosis: 553
HOETELMANS, R.M.W., MARIËN, K., DE PAUW, M., HILL, A., PEETERS, M., SEKAR, V., DE DONCKER, P., WOODFALL, B. & LEFEBVRE, E. Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers: 655
HOFMAN, A. *see* SCHELLEMAN, H.
HOMERY, M.-C. *see* CIVELLI, M.
HOPPU, K. *see* FANTA, S.
HOU, R.H. *see* SAMUELS, E.R.
HOUGHTON, P. *see* WIART, C.
HOUIN, G. *see* CONIL, J.M.
HOWELL, C., WILSON, A.D. & WARING, W.S. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases: 192
HUGHES, J., LOCKHART, J. & JOYCE, A. Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?: 83
HUITEMA, A.D.R. *see* JOERGER, M.
HUIZING, M.T. *see* JOERGER, M.
HURAULT, C. *see* DURRIEU, G.

ILES-SMITH, H. *see* ASARI, A.
IWASHIMA, K., YASUI-FURUKORI, N., KANEDA, A., SAITO, M., NAKAGAMI, T., SATO, Y. & KANEKO, S. No association between CYP2D6 polymorphisms and personality trait in Japanese: 96

JANG, S.B. *see* CHOI, J.H.
JESPERSEN, J.J. *see* BØNNELYKKE, K.
JIANG, F. *see* TANG, Y.-L.
JICK, H. *see* JICK, S.S.
JICK, S.S., KAYE, J.A. & JICK, H. Diclofenac and acute myocardial infarction in patients with no major risk factors: 662
JOERGER, M., HUITEMA, A.D.R., HUIZING, M.T., WILLEMSE, P.H.B., DE GRAEFF, A., ROSING, H., SCHELLENS, J.H.M., BEIJNEN, J.H. & VERMORKEN, J.B. Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic–pharmacodynamic study: 622
JOHNSON, M.A. *see* ASARI, A.
JOLLIET, P. *see* VICTORRI-VIGNEAU, C.
JONSSON, E.N. *see* KARLSSON, K.E.
JÖNSSON, S. *see* FANTA, S.
JOYCE, A. *see* HUGHES, J.
JULLIEN, V. *see* HIRT, D.
JULLIEN, V., RAÏS, A., URIEN, S., DIMET, J., DELAUGERRE, C., BOUILLON-PICHAULT, M., REY, E., PONS, G., BLANCHE, S. & TRÉLUYER, J.M. Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis: 105
JUNG, H.-E. *see* KIM, H.-S.

KABIR, Z., FEELY, J. & BENNETT, K. Primary care prescribing patterns in Ireland after the publication of large hypertension trials: 381
KAMARGASH, I. *see* GOLDSTEIN, L.H.
KANE, S.A. *see* VAN DER SCHUEREN, B.J.
KANEDA, A. *see* IWASHIMA, K.
KANEKO, S. *see* IWASHIMA, K.
KANG, H.-J. *see* KIM, H.-S.

KANG, S.H., POYNTON, M.R., KIM, K.M., LEE, H., KIM, D.H., LEE, S.H., BAE, K.S., LINARES, O., KERN, S.E. & NOH, G.J. Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis: 3
KANTESARIA, B. *see* GUPTA, S.K.
KARLSSON, K.E., GRAHNÉN, A., KARLSSON, M.O. & JONSSON, E.N. Randomized exposure-controlled trials; impact of randomization and analysis strategies: 266
KARLSSON, M.O. *see* FANTA, S.
KARLSSON, M.O. *see* KARLSSON, K.E.
KARLSSON, M.O. *see* LÖNNEBO, A.
KARLSTAD, Ø. *see* SAKSHAUG, S.
KAYE, J.A. *see* JICK, S.S.
KAYNAK, F. *see* UNVERIR, P.
KEATING, M.J. *see* MOULD, D.R.
KERN, S.E. *see* KANG, S.H.
KIM, D.H. *see* KANG, S.H.
KIM, E.-Y. *see* KIM, H.-S.
KIM, H.-S., SUNWOO, Y.E., RYU, J.Y., KANG, H.-J., JUNG, H.-E., SONG, I.-S., KIM, E.-Y., SHIM, J.-C., SHON, J.-H. & SHIN, J.-G. The effect of ABCG2 V12M, Q141K and Q126X, known functional variants *in vitro*, on the disposition of lamivudine: 645
KIM, K.H. *see* CHOI, J.H.
KIM, K.M. *see* KANG, S.H.
KIST-VAN HOLTHE, J.E. *see* VAN DER VORST, M.M.J.
KLOFT, C. *see* LEHR, T.
KLUNGEL, O.H. *see* DOBRE, D.
KLUNGEL, O.H. *see* GUMBS, P.D.
KLUNGEL, O.H. *see* SCHELLEMAN, H.
KOIVUVIITA, N. *see* TURPEINEN, M.
KOLZ, K. *see* GUPTA, S.K.
KORKMAZ, U. *see* CINEMRE, H.
KOTHARE, P.A. *see* LINNEBJERG, H.
KRÄHENBÜHL, S. *see* HAEGELI, L.
KRAMER, W. *see* DHAUN, N.
KRAUZE, T. *see* WYKRETOWICZ, A.
KRIBBEN, A. *see* STASS, H.
KUBITZA, D. *see* STASS, H.
KUHLMANN, J. *see* MOULD, D.R.
KUMAR, R. *see* MISHRA, B.

LACARELLE, B. *see* SOLAS, C.
LAFFONT, C.M. *see* DARTOIS, C.
LAGUERRE, J. *see* CONIL, J.M.
LAINE, K. *see* TURPEINEN, M.
LAMMERS, J.-W.J. *see* ESPOSITO-FESTEN, J.E.
LANGLEY, R.W. *see* SAMUELS, E.R.
LAPORTE, S. *see* BERGES, A.
LAVEILLE, C. *see* DARTOIS, C.
LAVIT, M. *see* CONIL, J.M.
LE GUELLEC, C. *see* BENETON, M.
LEATHARD, H. *see* BECKWITH, S.
LECHAT, P. *see* ANTIGNAC, M.
LECKRIDGE, R. Scottish GPs use of homeopathy: 397
LEE, D.K.C. *see* TAYAB, Z.R.
LEE, H. *see* KANG, S.H.
LEE, J.-E. *see* CHOI, J.H.
LEE, S.H. *see* KANG, S.H.
LEE, Y.J. *see* CHOI, J.H.
LEFEBVRE, E. *see* HOETELMANS, R.M.W.
LEHR, T., STAAB, A., TILLMANN, C., TROMMESHAUSER, D., RASCHIG, A., SCHAEFER, H.G. & KLOFT, C. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease: 36
LEMENUEL-DIOT, A. *see* DARTOIS, C.
LENNARD, M.S. *see* DICKINSON, G.L.
LEUNG, M. *see* PESCOVITZ, M.D.
LEWIS, B.C. *see* ELLIOT, D.J.
LEWIS, L.D. *see* ARONSON, J.K.
LEWIS, S. *see* MORTIMER, K.J.
LI, F.-M. *see* TANG, Y.-L.
LI, Q. *see* XIN, H.-W.
LI, W. *see* TANG, Y.-L.
LIN, N. *see* ZHANG, Y.
LINARES, O. *see* KANG, S.H.
LINNEBJERG, H., KOTHARE, P.A., PARK, S., MACE, K., REDDY, S., MITCHELL, M. & LINS, R. Effect of renal impairment on the pharmacokinetics of exenatide: 317
LINS, R. *see* LINNEBJERG, H.
LIP, G.Y.H. & WATSON, T. Stroke prevention in atrial fibrillation – things can only get better: 575
LIPWORTH, B.J. *see* TAYAB, Z.R.
LISI, M. *see* GORI, T.
LOCKHART, J. *see* HUGHES, J.
LONG, A.J. *see* CUI, Y.M.
LÖNNEBO, A., GRAHNÉN, A. & KARLSSON, M.O. An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers: 125
LOPEZ-SENDON, J.-L. *see* MORENO, R.
LOZANO, M.L. *see* GUERRERO, J.A.
LUNDGREN, S. *see* TURPEINEN, M.
LYLES, A. *see* BELL, J.S.

MA, Q. Development of oral anticoagulants: 263
MACE, K. *see* LINNEBJERG, H.
MACKAY, G.M. *see* FORREST, C.M.
MADJAR, M. *see* GOLDSTEIN, L.H.
MAGNÉ, N., ETIENNE-GRIMALDI, M.-C., CALS, L., RENÉE, N., FORMENTO, J.-L., FRANCOUAL, M. & MILANO, G. Dihydropyrimidine dehydrogenase activity and the IVS14+1G<A mutation in patients developing 5FU-related toxicity: 237
MAHMUD, A. *see* OKECHUKWU, I.
MAHMUD, A., BENNETT, K., OKECHUKWU, I. & FEELY, J. National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing: 706
MAI, A. & ASLANI, P. Impact of Vietnamese written and verbal medicine information on Vietnamese-speaking Australians' knowledge and satisfaction: 527
MAN, M.Z. *see* PETERKIN, V.C.
MANDELBROT, L. *see* HIRT, D.
MANTEL-TEEUWISSE, A.K. *see* GUMBS, P.D.
MAO, P. *see* TANG, Y.-L.
MARBURY, T. *see* GUPTA, S.K.
MARCUS, P. *see* FORST, T.
MARIËN, K. *see* HOETELMANS, R.M.W.
MARTÍNEZ, C. *see* GUERRERO, J.A.
MATHIE, R.T. & FISHER, P. Homeopathy is safe and does not lack positive evidence in clinical trials: 396
MAZOIT, J.-X. *see* BELOEIL, H.
MCCORMICK, P.A. *see* DONNELLAN, F.
MCFARLANE, L.C. *see* TAYAB, Z.R.
MCKAY, D. *see* PESCOVITZ, M.D.
MCLAY, J. *see* ROSS, S.
MCLAY, J. *see* TOBAIQY, M.
MCLAY, J.S. *see* STEWART, D.
MEHLOTRA, R.K., BOCKARIE, M.J. & ZIMMERMAN, P.A. *CYP2B6* 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment: 391
MELTON, L. *see* PESCOVITZ, M.D.
MELVILLE, V. *see* DHAUN, N.
MENNING, L. *see* PETERKIN, V.C.
MENTRÉ, F. *see* DARTOIS, C.
METSÄRINNE, K. *see* TURPEINEN, M.
MIETTUNEN, J. *see* TURPEINEN, M.
MILANO, G. *see* MAGNÉ, N.
MILEWSKA, A. *see* WYKRETOWICZ, A.
MILTON, J.C. & ABDULLA, A. Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's Wort: 717
MINERS, J.O. *see* ELLIOT, D.J.
MIREMONT-SALAMÉ, G. *see* ARIMONE, Y.
MISHRA, B. *see* SAHOO, S.
MISHRA, B., SADDICHHA, S., KUMAR, R. & AKHTAR, S. Risperidone-induced recurrent giant urticaria: 558
MISMETTI, P. *see* BERGES, A.
MITCHELL, A. *see* STASS, H.
MITCHELL, M. *see* LINNEBJERG, H.
MITCHELL, P.B. *see* TANG, Y.-L.
MOLIMARD, M. *see* ARIMONE, Y.
MÖLLER, J.-G. *see* STASS, H.
MONTASTRUC, J.L. *see* DURRIEU, G.
MONTGOMERY, K. *see* NATH, C.E.
MOORE, N. *see* ARIMONE, Y.
MORENO, R., FERNANDEZ, C., SANCHEZ-RECALE, A., CALVO, L., GALEOTE, G., SANCHEZ-AQUINO, R. & LOPEZ-SENDON, J.-L. Risk of stent

thrombosis after sirolimus or paclitaxel eluting coronary stent implantation: 110
MORTIMER, K.J., TATTERSFIELD, A.E., TANG, Y., WU, K., LEWIS, S., HOCHHAUS, G. & HARRISON, T.W. Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction: 439
MOULD, D.R., BAUMANN, A., KUHLMANN, J., KEATING, M.J., WEITMAN, S., HILLMEN, P., BRETTMAN, L.R., REIF, S. & BONATE, P.L. Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath©) in patients with chronic lymphocytic leukaemia and its link to treatment response: 278
MULGAONKAR, S. *see* PESCOVITZ, M.D.
MYRAND, S.P. *see* PETERKIN, V.C.

NADERER, O.J. *see* ASARI, A.
NAKAGAMI, T. *see* IWASHIMA, K.
NARCISSO, B. *see* BENETON, M.
NATH, C.E., SHAW, P.J., MONTGOMERY, K. & EARL, J.W. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients: 151
NAVARRO-NUÑEZ, L. *see* GUERRERO, J.A.
NOBLE, EDITED BY D. & TENDERA, M., NOBLE, D. Heart Rate Slowing by I_f Current Inhibition: 400
NOH, G.J. *see* KANG, S.H.

O'CONNOR, H. *see* TEELING, M.
OFORI, B., REY, E. & BÉRARD, A. Risk of congenital anomalies in pregnant users of statin drugs: 496
OKECHUKWU, I. *see* MAHMUD, A.
OKECHUKWU, I., MAHMUD, A., BENNETT, K. & FEELY, J. Choice of first antihypertensive – are existing guidelines ignored?: 722
ONDER, E. *see* CINEMRE, H.
OTTO, V. *see* ASARI, A.
OZDEMIR, V. *see* ZHANG, W.

PAKRAVAN, N., BATEMAN1, D.N. & GODDARD, J. Effect of acute paracetamol overdose on changes in serum and urine electrolytes: 824
PAN, A.X. *see* CUI, Y.M.
PARK, K. *see* CHOI, J.H.
PARK, S. *see* LINNEBJERG, H.
PARKER, J.D. *see* GORI, T.
PAULAUSKIS, J.D. *see* PETERKIN, V.C.
PEETERS, M. *see* HOETELMANS, R.M.W.
PELKONEN, O. *see* TURPEINEN, M.
PENG, D.D. *see* ZHANG, W.
PEREZ-RUIXO, J.J., CHEN, W., ZHANG, S., HAYES, S. & CHOW, A. Exposure-toxicity relationships for tipifarnib in cancer patients: 219
PESCOVITZ, M.D., VINCENTI, F., HART, M., MELTON, L., WHELCHEL, J., MULGAONKAR, S., MCKAY, D., LEUNG, M., CALLEJA, E. & BOUW, M.R. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients: 758
PETERKIN, V.C., BAUMAN, J.N., GOOSEN, T.C., MENNING, L., MAN, M.Z., PAULAUSKIS, J.D., WILLIAMS, J.A. & MYRAND, S.P. Limited influence of *UGT1A1*28* and no effect of *UGT2B7*2* polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes: 458
PFISTERER, M. *see* HAEGELI, L.
PFÜTZNER, A. *see* FORST, T.
PILLAI, GC. & STEIMER, J.-L. Commentary on Dartois *et al.* – model building in population PK–PD analyses. A 2002–2004 literature survey: 578
POIZOT-MARTIN, I. *see* SOLAS, C.
POMP, E. *see* THUNELL, S.
PONS, G. *see* HIRT, D.
PONS, G. *see* JULLIEN, V.
POYNTON, M.R. *see* KANG, S.H.
PRASANNA, C.G. *see* SUBBANNA, P.K.
PRATT, N. *see* ROUGHEAD, E.E.
PRETI, A.P.M. *see* CIVELLI, M.
PUHÓ, E. *see* BÁNHIDY, F.

QUARANTA, S. *see* SOLAS, C.

RAÏS, A. *see* JULLIEN, V.
RANCHOR, A.V. *see* DOBRE, D.
RANE, A. *see* TURPEINEN, M.
RASCHIG, A. *see* LEHR, T.
RATHGEN, K. *see* STANGIER, J.
REDDY, S. *see* LINNEBJERG, H.
REIF, S. *see* MOULD, D.R.
RENÉE, N. *see* MAGNÉ, N.
REPONEN, P. *see* TURPEINEN, M.
REY, E. *see* HIRT, D.
REY, E. *see* JULLIEN, V.
REY, E. *see* OFORI, B.
RICHARDSON, W.N. & HENDERSON, L. The safety of kava – a regulatory perspective: 418
RITTER, J.M. *see* ARONSON, J.K.
RIVERA, J. *see* GUERRERO, J.A.
ROCCA, H.P.B.-L. *see* HAEGELI, L.
RON-AVRAHAM, G. *see* GOLDSTEIN, L.H.
RONDELLI, I. *see* CIVELLI, M.
RØNNING, M. *see* SAKSHAUG, S.
ROSING, H. *see* JOERGER, M.
ROSS, S. *see* TOBAIQY, M.
ROSS, S., SIMPSON, C. & MCLAY, J. Authors' response: Homeopathy is safe and does not lack positive evidence in clinical trials/Scottish GPs use of Homeopathy: 398
ROSTAMI-HODJEGAN, A. *see* DICKINSON, G.L.
ROTH, W. *see* STANGIER, J.
ROTHUIZEN, L.E. *see* TSCHUPPERT, Y.
ROUF, A. *see* STEWART, D.
ROUGHEAD, E.E., PRATT, N. & GILBERT, A.L. Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes: 100
RYU, J.Y. *see* KIM, H.-S.

SADDICHHA, S. *see* MISHRA, B.
SAHOO, S., MISHRA, B. & AKHTAR, S. Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report: 715
SAITO, M. *see* IWASHIMA, K.
SAIVIN, S. *see* CONIL, J.M.
SAKSHAUG, S., FURU, K., KARLSTAD, Ø., RØNNING, M. & SKURTVEIT, S. Switching statins in Norway after new reimbursement policy – a nationwide prescription study: 476
SALEM, C.B. *see* HMOUDA, H.
SALEM, C.B., HMOUDA, H. & BOURAOUI, K. Glimepiride-induced vasculitis: a case report: 113
SAMII, K. *see* CONIL, J.M.
SAMUELS, E.R., HOU, R.H., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers: 591
SANCHEZ-AQUINO, R. *see* MORENO, R.
SANCHEZ-RECALE, A. *see* MORENO, R.
SANDERMAN, R. *see* DOBRE, D.
SATO, Y. *see* IWASHIMA, K.
SCHAEFER, H.G. *see* LEHR, T.
SCHÄFERS, R.F. *see* STASS, H.
SCHELLEMAN, H., KLUNGEL, O.H., WITTEMAN, J.C.M., HOFMAN, A., VAN DUIJN, C.M., DE BOER, A. & STRICKER, B.H.CH. Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis: 57
SCHELLENS, J.H.M. *see* JOERGER, M.
SCHÜTTE, K. *see* FORST, T.
SCHWARTZ, S. *see* GUPTA, S.K.
SEKAR, V. *see* HOETELMANS, R.M.W.
SHAW, P.J. *see* NATH, C.E.
SHEN, Y. *see* XIN, H.-W.
SHIM, J.-C. *see* KIM, H.-S.
SHIN, J.-G. *see* KIM, H.-S.
SHON, J.-H. *see* KIM, H.-S.
SI, D. *see* ZHANG, Y.

SICURO, S. *see* GORI, T.
SIEVENPIPER, J.L., EZATAGHA, A., DASCALU, A. & VUKSAN, V. When a placebo is not a 'placebo': a placebo effect on postprandial glycaemia: 546
SIMON, N. *see* SOLAS, C.
SIMPSON, C. *see* ROSS, S.
SINCLAIR, S.R. *see* VAN DER SCHUEREN, B.J.
SINGH, N.K. Polonium-210 in news: an allegory of a misappropriated science: 714
SITARAS, N.M. *see* BONOVAS, S.
SKURTVEIT, S. *see* BRAMNESS, J.G.
SKURTVEIT, S. *see* SAKSHAUG, S.
SLIM, R. *see* HMOUDA, H.
SMITH, T. *see* FORST, T.
SMITH, W. *see* GUPTA, S.K.
SNAITH, A. *see* STEWART, D.
SOLAS, C., SIMON, N., DROGOUL, M.-P., QUARANTA, S., FRIXON-MARIN, V., BOURGAREL-REY, V., BRUNET, C., GASTAUT, J.-A., DURAND, A., LACARELLE, B. & POIZOT-MARTIN, I. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients: 353
SONG, I.-S. *see* KIM, H.-S.
SOSTEK, M.B., CHEN, Y. & ANDERSSON, T. Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole: 386
SOUVEREIN, P.C. *see* GUMBS, P.D.
SPECTOR, R.G. John Trounce: 116
STAAB, A. *see* LEHR, T.
STÄHLE, H. *see* STANGIER, J.
STANGIER, J., RATHGEN, K., STÄHLE, H., GANSSER, D. & ROTH, W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects: 292
STASS, H., BÜHRMANN, S., MITCHELL, A., KUBITZA, D., MÖLLER, J.-G., KRIBBEN, A., WENZEL, R.R. & SCHÄFERS, R.F. The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction: 745
STAVROS, F. *see* DHAUN, N.
STEIMER, J.-L. *see* (COLIN) PILLAI, G.
STEWART, D., ROUF, A., SNAITH, A., ELLIOTT, K., HELMS, P.J. & MCLAY, J.S. Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey: 90
STOLFO, G.D. *see* GORI, T.
STONE, T.W. *see* FORREST, C.M.
STOY, N. *see* FORREST, C.M.
STRICKER, B.H.CH. *see* SCHELLEMAN, H.
SU, D. *see* XIN, H.-W.
SUBBANNA, P.K., PRASANNA, C.G. & GUNALE, B.K. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients: 245
SUHARJONO, *see* ELLIOT, D.J.
SUNWOO, Y.E. *see* KIM, H.-S.
SWAN, S. *see* DHAUN, N.
SWAN, S.K. *see* GUPTA, S.K.
SZABADI, E. *see* SAMUELS, E.R.

TANG, Y. *see* MORTIMER, K.J.
TANG, Y.-L., MAO, P., LI, F.-M., LI, W., CHEN, Q., JIANG, F., CAI, Z.-J. & MITCHELL, P.B. Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia: 49
TANSEY, T. *see* CHURCH, R.
TARRAL, A. *see* CIVELLI, M.
TATTERSFIELD, A.E. *see* MORTIMER, K.J.
TAYAB, Z.R., FARDON, T.C., LEE, D.K.C., HAGGART, K., MCFARLANE, L.C., LIPWORTH, B.J. & HOCHHAUS, G. Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate: 698
TEELING, M., O'CONNOR, H., FEELY, J. & BENNETT, K. What therapies have replaced rofecoxib in Ireland?: 536
TENDERA, M. *see* NOBLE, D.
TENG, C.H. *see* CUI, Y.M.
THAKRAR, B.T., GRUNDSCHOBER, S.B. & DOESSEGGER, L. Detecting signals of drug–drug interactions in a spontaneous reports database: 489
THANACOODY, H.K.R. Thioridazine: resurrection as an antimicrobial agent?: 566
THEUMA, R. *see* FRENDO, M.
THÉVENIN, A. *see* BELOEIL, H.
THUNELL, S., POMP, E. & BRUN, A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias: 668
TIDDENS, H.A.W.M. *see* ESPOSITO-FESTEN, J.E.
TILLMANN, C. *see* LEHR, T.
TJAN, D.H.T. *see* HOELEN, D.W.M.
TOBAIQY, M., MCLAY, J. & ROSS, S. Foundation year 1 doctors and clinical pharmacology and therapeutics teaching. A retrospective view in light of experience: 363
TOLONEN, A. *see* TURPEINEN, M.
TOPACOGLU, H. *see* UNVERIR, P.
TRANCHAND, B. *see* BERGES, A.
TRANCHAND, B. *see* DARTOIS, C.
TRÉLUYER, J.M. *see* JULLIEN, V.
TRELUYER, J.-M. *see* HIRT, D.
TROMMESHAUSER, D. *see* LEHR, T.
TSANTES, A. *see* BONOVAS, S.
TSCHUPPERT, Y., BUCLIN, T., ROTHUIZEN, L.E., DECOSTERD, L.A., GALLEYRAND, J., GAUD, C. & BIOLLAZ, J. Effect of dronedarone on renal function in healthy subjects: 785
TUCKER, G.T. *see* DICKINSON, G.L.
TURPEINEN, M., KOIVUVIITA, N., TOLONEN, A., REPONEN, P., LUNDGREN, S., MIETTUNEN, J., METSÄRINNE, K., RANE, A., PELKONEN, O. & LAINE, K. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites: 165

UNVERIR, P., TOPACOGLU, H., BOZKURT, S. & KAYNAK, F. Cardiovascular toxicity due to metoprolol poisoning in a patient with coronary artery disease: 694
UPTON, R.N. *see* FORNASINI, G.
URIEN, S. *see* ANTIGNAC, M.
URIEN, S. *see* HIRT, D.
URIEN, S. *see* JULLIEN, V.

VAN DER HEIJDEN, A.J. *see* VAN DER VORST, M.M.J.
VAN DER MEER, Y.G. *see* HOELEN, D.W.M.
VAN DER SCHUEREN, B.J., DE HOON, J.N., VANMOLKOT, F.H., VAN HECKEN, A., DEPRE, M., KANE, S.A., DE LEPELEIRE, I. & SINCLAIR, S.R. Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging: 580
VAN DER VORST, M.M.J., KIST-VAN HOLTHE, J.E., DEN HARTIGH, J., VAN DER HEIJDEN, A.J., COHEN, A.F. & BURGGRAAF, J. Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery: 796
VAN DER WIEL, H.E. *see* HÄRMARK, L.
VAN DUIJN, C.M. *see* SCHELLEMAN, H.
VAN GROOTHEEST, A.C. *see* HÄRMARK, L.
VAN HECKEN, A. *see* VAN DER SCHUEREN, B.J.
VAN PUIJENBROEK, E.P. *see* DE GROOT, M.C.H.
VAN SONDEREN, E. *see* DOBRE, D.
VAN VELDHUISEN, D.J. *see* DOBRE, D.
VAN VUGT, R. *see* HOELEN, D.W.M.
VAN ZANTEN, A.R.H. *see* HOELEN, D.W.M.
VANMOLKOT, F.H. *see* VAN DER SCHUEREN, B.J.
VERMORKEN, J.B. *see* JOERGER, M.
VERSCHUREN, W.M.M. *see* GUMBS, P.D.
VEYRAC, G. *see* VICTORRI-VIGNEAU, C.
VICENTE, V. *see* GUERRERO, J.A.

VICTORRI-VIGNEAU, C., DAILLY, E., VEYRAC, G. & JOLLIET, P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey: 198
VINCENTI, F. *see* PESCOVITZ, M.D.
VISSER, S.T. *see* ATTHOBARI, J.
VUKSAN, V. *see* SIEVENPIPER, J.L.

WALLER, D.G. Drugs and the kidney: more than a question of dose: 719
WALLER, D.G. Off-label and unlicensed prescribing for children: have we made any progress?: 1
WANG, A. *see* ZHANG, W.
WANG, L.-C. *see* ZHANG, W.
WANG, Z. *see* GUPTA, S.K.
WARING, W.S. *see* HOWELL, C.
WATSON, T. *see* LIP, G.Y.H.
WEBB, D.J. *see* DEAR, J.W.
WEBB, D.J. *see* DHAUN, N.
WEITMAN, S. *see* MOULD, D.R.
WENK, M. *see* HAEGELI, L.
WENZEL, R.R. *see* STASS, H.
WHELCHEL, J. *see* PESCOVITZ, M.D.
WIART, C. & HOUGHTON, P. Ethnopharmacology of Medicinal Plants: Asia and the Pacific: 248
WILLEMSE, P.H.B. *see* JOERGER, M.
WILLIAMS, J.A. *see* PETERKIN, V.C.
WILSON, A.D. *see* HOWELL, C.
WISE, S.D. *see* CUI, Y.M.
WITTEMAN, J.C.M. *see* SCHELLEMAN, H.
WOODFALL, B. *see* HOETELMANS, R.M.W.
WU, K. *see* MORTIMER, K.J.
WU, X.-C. *see* XIN, H.-W.
WYKRETOWICZ, A., GUZIK, P., KRAUZE, T., ADAMSKA, K., MILEWSKA, A. & WYSOCKI, H. Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation: 792
WYSOCKI, H. *see* WYKRETOWICZ, A.

XIE, Q.-Y. *see* ZHANG, W.
XIE, W. *see* ZHANG, W.
XIN, H.-W., WU, X.-C., LI, Q., YU, A.-R., ZHU, M., SHEN, Y., SU, D. & XIONG, L. Effects of *Schisandra sphenanthera* extract on the pharmacokinetics of tacrolimus in healthy volunteers: 469
XIONG, L. *see* XIN, H.-W.
XU, L.-Y. *see* ZHANG, W.

YASUI-FURUKORI, N. *see* IWASHIMA, K.
YEO, K.P. *see* CUI, Y.M.
YU, A.-R. *see* XIN, H.-W.
YUEN, E. *see* CUI, Y.M.
YUEN, G.J. *see* ASARI, A.

ZANEN, P. *see* ESPOSITO-FESTEN, J.E.
ZHANG, S. *see* PEREZ-RUIXO, J.J.
ZHANG, W., CHEN, B.-L., OZDEMIR, V., HE, Y.-J., ZHOU, G., PENG, D.D., DENG, S., XIE, Q.-Y., XIE, W., XU, L.-Y., WANG, L.-C., FAN, L., WANG, A. & ZHOU, H.-H. *SLCO1B1* 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients: 346
ZHANG, Y., SI, D., CHEN, X., LIN, N., GUO, Y., ZHOU, H. & ZHONG, D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects: 67
ZHAO, X. *see* CUI, Y.M.
ZHONG, D. *see* ZHANG, Y.
ZHOU, G. *see* ZHANG, W.
ZHOU, H. *see* ZHANG, Y.
ZHOU, H.-H. *see* ZHANG, W.
ZHOU, Y. *see* CUI, Y.M.
ZHU, M. *see* XIN, H.-W.
ZIMMERMAN, P.A. *see* MEHLOTRA, R.K.
ZUFFEREY, P. *see* BERGES, A.

DOI:10.1111/j.1365-2125.2007.03075.x

SUBJECT INDEX

This index was compiled from the keywords

3TC, 738
5-amino levulinate synthase, 668
5-fluorouracil, 613
ABCG2, 645
absorption, 804
ACE inhibitors, 100, 792
ACTH, 125
activated partial thromboplastin time, 292
active metabolite, 36
acute coronary syndrome, 694
acute interstitial nephritis, 819
acute myocardial infarction, 662
adherence to regulations, 476
adrenergic vasoconstriction, 421
adverse drug reactions, 542, 233, 482, 819
aerosols, 241
alertness, 591
Alzheimer's disease, 36
analgesic therapy, 75
antihypertensive, 381
antihypertensive drugs, 57
antihypertensives, 722
antilipademic agents, 496
antimicrobial, 566
antiplatelet, 100
antiretroviral drugs, 391
antithrombotic therapy, 706
arrhythmia, 192
arterial stiffness, 792
arthritis, 517
asthma, 241, 328, 439
atherosclerosis, 57
atomoxetine, 445
atrial fibrillation, 706
attitudes, 90
axon reflex, 421

β-blocker poisoning, 694
bibliometry, 603
bupropion, 165
burn patients, 27

calcitonin gene-related peptide, 580
calcium antagonists, 83
CAM, 546
cancer patients, 219
capsaicin, 580
cardiac surgery, 796
cardio-renal, 810
cardiotoxicity, 192
cardiovascular, 100
carisoprodol, 210
causality assessment, 482
ceftazidime, 27
chemoprevention, 255
CHF 4227, 304
children, 105, 151, 241
Chinese, 445
Chinese race, 49
ciclosporin, 758
ciclosporin (cyclosporine A), 772
circadian variation, 125
cirrhosis, 550
clindamycin, 542
clinical pharmacokinetics, 67
clinical pharmacology and therapeutics, 363
clinical trial simulation, 14, 266
clozapine, 49
community pharmacy, 90
congenital anomalies, 496
consumer, 527
continual reassessment method, 686
continuous intravenous furosemide, 796
co-prescription, 536
cord plasma concentrations, 634
coronary heart disease, 346
cortisol, 125
COX-2 inhibitors, 536
COX-inhibitors, 824
creatinine clearance, 785
cyclo-oxygenase (COX), 824
CYP2B6, 391
CYP2C18, 450
CYP2C19, 67, 450
CYP2C9, 450
CYP2C9, 67
CYP2D6, 96, 445
CYP2D6*10, 445
CYP3A4, 772
CYP3A5, 185, 353
cytochrome P-450 enzyme system, 668
cytochrome P450, 14, 165, 450
cytokines, 517

dabigatran etexilate, 292
dabigatran, 292
darkness reflex, 591
darunavir, 655
desensitization, 421
desloratadine, 174
developmental, 772
diabetes, 100
diabetes, 546
diclofenac, 662
dietary supplements, 373
digoxin, 706
dihydropyrimidine dehydrogenase, 237
direct thrombin inhibitor, 292
domperidone, 591
dose, 174
dose–effect, 686
doxazosin, 792
dronedarone, 785
drug costs, 476
drug development, 566
drug effectiveness, 406
drug interactions, 373
drug metabolism, 14
drug monitoring, 428, 613
drug overdose, 192
drug resistance, 566
drug safety, 622
drug therapy, 668
drug use, 810
drug utilisation, 100
drug–drug interactions, 489
dysgeusia, 542

ecarin clotting time, 292
efavirenz, 391
elderly, 428
electrocardiograph, 192
electroencephalographic approximate entropy, 3
endothelial dysfunction, 792
endothelin, 733
endothelium, 145
end-stage renal disease, 317
enoxaparin, 428
ergotamine, 510
esomeprazole capsules, 386
ESRD, 738
exenatide, 317
exposure–response, 278

flavonoid, 133
fluoropyrimidine, 237
fluticasone propionate, 698
food–drug interactions, 386
foundation programme doctors, 363
fractional excretion of electrolytes, 824
functional polymorphism, 346
furosemide, 804

gastro-oesophageal reflux disease, 83
gender, 49
gene polymorphism, 237
general population, 810
generic, 680
genotype, 96
ginseng, 546
gliclazide, 67, 450
glucose, 546
glypressin, 550
guidelines, 722

© 2007 Blackwell Publishing Ltd

haematological malignancy, 255
haemodialysis, 335
healthy volunteers, 469
heart failure, 406
HEK 293T cells, 133
herbal medicine, 373
herb-drug interactions, 373
HIV, 105, 634
HPA axis, 125
human liver microsomes, 458

in silico, 14
incretin mimetic, 317
indinavir, 353
indirect response model, 278
infants, 796
inhaled corticosteroid, 439
inpatients, 373
interaction, 655
interethnic variation, 346
interferon alfa-2b, 726
internal medicine, 373
intrauterine growth retardation, 510
ischaemia, 145
ischaemic complications, 550

Japanese, 96

kidney, 750
kynurenine, 517

lamivudine, 645, 738
L-carnitine, 335
LDL cholesterol, 304
light reflex, 591
lipid lowering therapy, 100
liver impairment, 622
logistic regression, 278
low birth weight, 510
low-molecular-weight heparin, 428

markers of bone metabolism, 304
MDR1, 185
MDR1, 353
measure of interaction, 489
medical students, 233
medicalization, 810
melatonin, 517
melphalan, 151
meprobamate, 210
meta-analysis, 255
metoprolol poisoning, 694
migraine therapy, 580
model building, 603
model validation, 278
model-based analysis, 266
modelling and simulation, 14
modelling, 125, 335
mometasone furoate, 698
monodisperse aerosols, 328
Moxifloxacin, 745
multiplicative and additive models, 489
muscle, 335
mycophenolate mofetil, 758

nefopam, 686
nelfinavir, 634
neopterin, 517
nephrotoxicity, 824
neural network model, 3
NMDA receptor antagonist, 75
noncardiac chest pain, 83
nonlinear mixed effect model, 603
nonlinear pharmacokinetics, 278
NONMEM, 36, 151, 278, 428, 634
non-steroidal anti-inflammatory drugs (NSAIDs), 824
noradrenaline, 421
North America, 391
Norway, 476
NS2330, 36
NSAIDs, 536, 662

observational studies, 406
observational study, 662
off-label prescribing, 90
ordinary sigmoid E_{max} model, 3
organic cation transport, 785

paclitaxel, 622
paediatric, 174, 772
paediatrics, 90
painful neuropathy, 75
Papua New Guinea, 391
paracetamol, 824
patient safety, 363
patient-related variables, 49
pegylation, 726
peritoneal dialysis, 738
personality, 96
P-glycoprotein, 353
pharmacist, 527
pharmacodependence, 198
pharmacodynamic, 603
pharmacodynamics, 292, 804
pharmacoepidemiological, 706
pharmacoepidemiology, 210, 476
pharmacogenetic variation, 346
pharmacogenetics, 14, 57, 237
pharmacogenetics, 57
pharmacokinetic, 428, 603, 733
pharmacokinetics, 105, 165, 174, 185, 219, 233, 317, 335, 353, 386, 445, 469, 613, 622, 645, 726, 738, 745, 758, 804
pharmacology, 439
pharmacometrics, 266
pharmacovigilance, 233, 542
placebo effect, 546
placental transfer, 634
plasma levels, 49
plasma protein binding, 698
platelets, 133
poisoning, 192
polymorphism, 67, 185, 458, 645
polymorphisms, 57
population analysis, 622
population model, 603
population pharmacokinetic modelling, 36
population pharmacokinetics, 151, 27, 750, 772
population pharmacokinetics-pharmacodynamics, 125
porphyrias, 668
porphyrinogenicity, 668
porphyrogenicity, 668
postprandial, 546
pramipexole, 591
pravastatin efficacy, 346
pregnancy registry, 496
pregnancy, 496, 510
prescribing, 363, 381, 722
prescription database, 476
prescription drug abuse, 210
preterm birth, 510
proton pump inhibitors, 536, 819
pulmonary deposition, 698
pupil, 591

QT prolongation, 566
questionnaire, 90, 363

randomized concentration-controlled trial, 266
randomized dose-controlled trial, 266
reaction phenotyping, 450
remifentanil, 3
renal failure, 165
renal impairment, 317, 733
renal insufficiency, 726
renal transplant, 758
renal transplantation, 772
reperfusion, 145
reproducibility, 580
risk, 233
ritonavir, 655
rofecoxib, 536

safety monitoring, 192
safety, 174
salbutamol, 241
savings, 680
Schisandra sphenanthera extract, 469
schizophrenia, 49
screening, 810
SERM, 304
severe renal dysfunction, 745
sex, 36
single and multiple dose trial, 304
single nucleotide polymorphism, 353
sirolimus, 758
sitaxsentan, 733
SLCO1B1, 346
smooth muscle cells, 133
social pharmacology, 233
spontaneous reporting, 819
statins, 255, 476, 496, 680
stavudine, 105
steroids, 328
study design, 266
sublingual administration, 804
survey, 90

sympathetic nervous system, 421
systemic side-effects, 698

tacrolimus, 185, 469, 750
taste disorder, 542
tenofovir disoproxil fumarate, 655
thioridazine, 566
tipifarnib, 219
TMC114, 655
tolerance, 796
toxicity, 219, 237, 796
TP signaling, 133
transplantation, 750
trials, 381
tryptophan, 517
tuberculosis, 566
Type 2 diabetes, 317

UDP-glucuronosyltransferases, 458
*UGT1A1*28*, 458
*UGT2B7*2*, 458

vasodilation, 580
venovenous haemodialysis, 745
Vietnamese, 527

West Africa, 391
written medicine information, 527

Zeffix™, 738
zolpidem, 198

DOI:10.1111/j.1365-2125.2007.03076.x

The Editors are grateful to the following who have reviewed for the *Journal* in 2007:

L.J. Aarons
J. Abdullah
D.R. Abernethy
I. Abubakar
I. Adcock
F. Akhlaghi
T. Akizawa
E. Alborch
A. Alfirevic
J. Allen
L. Almond
C. Anderson
N. Antonakis
M. Ashton
J. Atthobari
T. Avery
I. Aziz
A. Azzi
D. Back
J.T. Backman
H. Bagheri
D.G. Bailey
C. Balduini
H. Baran
T. Barnes
M. Barnett
D.N. Bateman
P. Baumann
E. Begg
S. Bellary
H.A. Benson
M. Bermejo
L. Bertilsson
J.S. Bertino
J.H. Beumer
D. Bhattacharya
R. Bies
J. Biollaz
D. Birkett
P. Bitsios
G.E. Blakey
A. Boddy
M. Boffito
C. Borghi
L. Borgstrom
M.-H. Bouchard
X. Boulenc
I.W. Boyd
R.C. Bracchi
A.J. Brady
S. Brain
A.E. Bravo
A. Breckenridge
C. Breen
O. Brodde
K. Brosen
E. Brown
E. Bruckert
R. Buckham
R. Buckingham
T. Buclin
K. Budde
D. Burger
J. Burggraaf
R.W. Caldwell
J.T. Callaghan
S. Callies
C. Cameron
K. Carlsson
G. Carr-White
A. Carvajal
J. Chan
B. Chapman
B.G. Charles
E. Chatelut
Y. Chen
Y.F. Cheung
B. Cheung
I. Choonara
B. Chowbay
P.J. Chowienczyk
A. Choy
J. Christensen
H. Chrystyn
G. Chu
M. Church
D.W. Clark
P.S. Collier
S.A. Constable
S.J. Cooper
M. Coughtrie
J.-L. Cracowski
M. Crook
M. Curtis
M. Cutolo
J.M. Dalrymple
A. Daly
P. Dargan
A. Dasgupta
P. Davey
G. Dawson
R.O. Day
M.C. de Groot
N.K. de Boer
L.T. de Jong-van den Berg
C. De Las Cuevas
C. de Vries
R. Dehoff
J.A. Delaney
O. DellaPasqua
H. Derendorf
Z. Desta
A. DiPaolo
G. Dickinson
R. Dixon
K. Donaldson
P. Donnan
M.P. Doogue
S. Duffull
C. Duggan
R. Eccles
G.I. Edwards
R. Edwards
M. Egorin
A. el Sakka
S. Ellenberg
B. Emrecan
L. Endrenyi
E. Ernst
V. Evangelista
A. Evans
S. Evans
M. Everard
C. Fadul
C. Falcoz
V. Fanos
T. Fardon
J. Feely
M. Feely
R. Ferner
A. Ferro
R.J. Flanagan
G.A. Ford
D.J. Foster
K.L. Franson
P. Friedman
M. Frisher
U. Fuhr
A. Fujimura
T. Furuta
L. Fuso
A. Gaedigk
J. Gagnier
M. Galderisi
A. Galetin
K. Gallicano
L. Garattini
S.J. Gardiner
G. Geisslinger

© 2007 Blackwell Publishing Ltd

E. Gerdts
A. Gilbert
D. Goldsmith
I. Gonda
A. Gonzalo-Garijo
A. Gorchein
T. Gori
G.G. Graham
D. Graham
G. Graham
T. Grasela
C. Green
D.J. Greenblatt
A. Gross
M. Grube
HJ. Guchelaar
I. Gueoguieva
J. Gulbinovic
J.F. Haas
N. Haley
S.D. Hall
I. Hall
A. Hamberg
A. Hansell
S. Harbarth
M. Hauben
J. Haughney
P.J. Helms
L. Hendeles
L. Henderson
C. Hernandez-Lopez
D.A. Hesselink
R. Hift
N. Holford
D.M. Homa
M. Homma
J.M. Hoskins
B. Houston
R.L. Howard
S.-L. Hsu
S. Hudson
J.G. Hugtenburg
A.D. Huitema
T. Hyde
I. Idris
K.F. Iett
B.P. Imbimbo
M. Ingelman-Sundberg
S.H. Ingwersen
G.K. Isbister
K.P. Ittner
P.R. Jackson
G. Jackson
E. Jacqz-Aigrain
I.-J. Jang
E. Jannini
H. Janssens
J. Jeremy
Y. Ji
S.S. Jick
Y. Jin
S. Johannessen
T.N. Johnson
J. Johnson
A. Johnston
S. Jönsson
K.M. Jorga
W. Jusko
N.R. Kahan
J.-Y. Kang
H. Kankaanranta
S. Kasper
D.A. Katz
F. Keller
C. Kelly
K. Kenworthy
T. Kerbusch
T. Kettle
J.T. Kielstein
P. Kiely
J. Kirchheiner
C.M. Kirkpatrick
K.T. Kivisto
I. Klebovich
C.A. Knibbe
J.M. Kovarik
W. Krauwinkel
M. Krousel-Wood
L. Kuitert
T. Kuwaki
J. Lacey
M. Lader
J.M. Lanao
N.J. Langford
M.J. Langman
F. Lavorini
S. Leask
A. Leaver
V.W. Lee
J. LeLorier
A. Lemenuel
M. Levine
L.D. Lewis
M.J. Lewis
M. Li
C.J. Lin
G. Lip
B. Lipworth
M. Lohitnavy
Y.K. Loke
F. Lokiec
R. MacAllister
T. MacDonald
M. MacLeod
P. Madeddu
I. Mahmood
M. Malik
A. Malizia
A.A. Mangoni
A. Mant
T. Mant
P. Marquet
K.M. Marshall
S. Marshall
J.H. Martin
U. Martin
M. Martinez-Gomez
D. Matthews
S. Maxwell
P. McCormack
J. McEwen
G. McInnes
M. McKean
W. McKerrow
A.J. McLachlan
J.S. McLay
V.M. Meidan
I. Meineke
P.A. Meredith
M.C. Michel
D.P. Mikhailidis
G. Mikus
G. Milano
J.O. Miners
P. Minuz
A.A. Mitchell
A.J. Mitchell
J.E. Møller
M.R. Moore
L. Morgan
J.C. Mountford
J. Mucklow
M.L. Muiesan
K.T. Muir
G. Muirhead
H. Mulder
H. Mulla
T.F. Munzel
H. Mwandumba
A.N. Nafziger
G.G. Nahum
D. Naisbitt
U. Narhi
K. Nassem
C.E. Nath
P. Neuvonen
W. Newman
L.P. Nielsen

M. Niemi
L.J. Nilsson
P. Nony
D. Nutt
K. Ogungbenro
P. O'Kane
G. Onder
K.L. Ong
A. Owen
B. Park
J. Paxton
B. Peng
S.R. Penzak
M.A. Perazella
A.M. Persky
A.H. Petersen
J.R. Petrie
W. Pichler
A. Pilbrow
H. Pinnock
M. Pirmohamed
D. Plowchalk
I. Poggesi
K. Porter
C.V. Powell
R. Purkiss
I. Ragueneau-Majlessi
R. Rahavendran
P. Reading
C. Rebouche
S. Redwood
J. Rengelshausen
E. Renzoni
A. Rettie
B. Richardson
B. Riou
J.M. Ritter
L. rivory
M. Roberts
R. Roberts
J. Robertson
R. Robson
L.A. Rodríguez
P. Rolan
F. Rombout
B. Rosenkranz
J. Rossert
A. Rostami-Hodjegan
E.E. Roughead
A. Rousseau
L. Ruilope
B.C. Sallustio
M. Sánchez-Borges
M. Schachter
M.B. Scharf
F. Schobben
M. Schulz
U.I. Schwarz
D. Scott
P. Seale
C. Sevcik
G. shenfield
G. Shepherd
J.-G. Shin
A. Shore
U. Simeoni
N. Simon
D.R. Singer
S. Singh
T. Skaar
C.C. Skarke
L.A. Skoglund
J. Slattery
A.J. Smith
D. Smith
I. Smith
P. Smith
S. Smith
E. Spina
L. Spurling
C.E. Staatz
L. Steardo
D. Stewart
R. Stienstra
B. Sunderland
R. Suvarna
K.K. Teo
S.H. Thomas
S. Thomas
A. Thomson
K. Tihanyi
P.J. Tobin
B. Tomlinson
C. Tomson
A. Tonkin
S. Toon
B. Tranchand
I.F. Troconiz
A. Tso
Y. Uresin
O. Usmani
B. Valenzuela
H.J. van Kan
T.P. van Staa
J. van Gerven
R. van Hest
A. van Peer
J. Vella-Brincat
S. Veltkamp
K. Venkatakrishnan
R. Venkataramanan
J.T. Visser
A.I. Vitry
R. Vivancos
G. Volans
O. vonRichter
B.C. Vrijens
M. Wadelius
P. Waller
T. Walley
K. Walsh
R. Walsky
A. Wang
J. Wang
T. Warner
M. Watson
M. Weatherall
B. Weatherley
D. Webb
B. Weber-Hamann
M. Weiss
M.M. Werler
N.J. White
S. White
M. Whitehouse
A.S. Wierzbicki
K. Wilk
I. Wilkinson
D. Williams
T.E. Wilson
P. Wilson
S. Wilson
F. Witter
S.Y. Wong
G. Wong
A. Woodiwiss
D.J. Wright
C. Wright
D. Wright
F.L. Wu
C. Wynne
H. Yamazaki
J. Yang
R. Yates
P. Yazdani-Brojeni
N.D. Yeomans
D. Yim
M. Young
U. Zanger
H.-H. Zhou
Y. Zhou
I. Zineh
B. Zunkler

Contents

Volume 64, Number 1, July 2007

Editors' view

1 Off-label and unlicensed prescribing for children: have we made any progress?: *D.G. Waller*

Pharmacokinetics & pharmacodynamics

3 Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis: *S.H. Kang, M.R. Poynton, K.M. Kim, H. Lee, D.H. Kim, S.H. Lee, K.S. Bae, O. Linares, S.E. Kern & G.J. Noh*

14 The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies – *CYP2C9* and warfarin as an example: *G.L. Dickinson, M.S. Lennard, G.T. Tucker & A. Rostami-Hodjegan*

Pharmacokinetics

27 A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation: *J.M. Conil, B. Georges, M. Lavit, J. Laguerre, K. Samii, G. Houin & S. Saivin*

36 Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease: *T. Lehr, A. Staab, C. Tillmann, D. Trommeshauser, A. Raschig, H.G. Schaefer & C. Kloft*

49 Gender, age, smoking behaviour and plasma clozapine concentrations in 193 Chinese inpatients with schizophrenia: *Y.-L. Tang, P. Mao, F.-M. Li, W. Li, Q. Chen, F. Jiang, Z.-J. Cai & P.B. Mitchell*

Pharmacogenetics

57 Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis: *H. Schelleman, O.H. Klungel, J.C.M. Witteman, A. Hofman, C.M. van Duijn, A. de Boer & B.H. CH. Stricker*

67 Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects: *Y. Zhang, D. Si, X. Chen, N. Lin, Y. Guo, H. Zhou & D. Zhong*

Drug safety

75 Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain: *T. Forst, T. Smith, K. Schütte, P. Marcus & A. Pfützner*

Therapeutics

83 Do calcium antagonists contribute to gastro-oesophageal reflux disease and concomitant noncardiac chest pain?: *J. Hughes, J. Lockhart & A. Joyce*

90 Attitudes and experiences of community pharmacists towards paediatric off-label prescribing: a prospective survey: *D. Stewart, A. Rouf, A. Snaith, K. Elliott, P.J. Helms & J.S. McLay*

Short reports

96 No association between CYP2D6 polymorphisms and personality trait in Japanese: *K. Iwashima, N. Yasui-Furukori, A. Kaneda, M. Saito, T. Nakagami, Y. Sato & S. Kaneko*

100 Trends over 5 years in cardiovascular medicine use in Australian veterans with diabetes: *E.E. Roughead, N. Pratt & A.L. Gilbert*

105 Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis: *V. Jullien, A. Raïs, S. Urien, J. Dimet, C. Delaugerre, M. Bouillon-Pichault, E. Rey, G. Pons, S. Blanche & J.M. Tréluyer*

Letters to the editors

110 Risk of stent thrombosis after sirolimus or paclitaxel eluting coronary stent implantation: *R. Moreno, C. Fernandez, A. Sanchez-Recale, L. Calvo, G. Galeote, R. Sanchez-Aquino & J.-L. Lopez-Sendon*

113 Glimepiride-induced vasculitis: a case report: *C.B. Salem, H. Hmouda & K. Bouraoui*

Book review

115 Oxford Handbook of Nurse Prescribing: *Edited by S. Beckwith & P. Franklin; reviewed by H. Leathard*

Obituary

116 John Trounce: *R.G. Spector*

118 Erratum

Volume 64, Number 2, August 2007

Editors' view

119 An agenda for research on adverse drug reactions: *J.K. Aronson*

Commentary

122 Disease mongering – a challenge for everyone involved in healthcare: *J.W. Dear & D.J. Webb*

Pharmacokinetics & pharmacodynamics

125 An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers: *A. Lönnebo, A. Grahnén & M.O. Karlsson*

133 Flavonoids inhibit the platelet TxA2 signalling pathway and antagonize TxA2 receptors (TP) in platelets and smooth muscle cells: *J.A. Guerrero, L. Navarro-Nuñez, M.L. Lozano, C. Martínez, V. Vicente, J.M. Gibbins & J. Rivera*

145 Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight: *T. Gori, G.D. Stolfo, S. Sicuro, S. Dragoni, M. Lisi, S. Forconi & J.D. Parker*

Pharmacokinetics

151 Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients: *C.E. Nath, P.J. Shaw, K. Montgomery & J.W. Earl*

165 Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites: *M. Turpeinen, N. Koivuviita, A. Tolonen, P. Reponen, S. Lundgren, J. Miettunen, K. Metsärinne, A. Rane, O. Pelkonen & K. Laine*

174 Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults: *S.K. Gupta, B. Kantesaria, C. Banfield & Z. Wang*

Pharmacogenetics

185 Influence of the *CYP3A5* and *MDR1* genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects: *J.H. Choi, Y.J. Lee, S.B. Jang, J.-E. Lee, K.H. Kim & K. Park*

Drug safety

192 Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases: *C. Howell, A.D. Wilson & W.S. Waring*

198 Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey: *C. Victorri-Vigneau, E. Dailly, G. Veyrac & P. Jolliet*

210 Carisoprodol use and abuse in Norway. A pharmacoepidemiological study: *J.G. Bramness, K. Furu, A. Engeland, & S. Skurtveit*

Therapeutics

219 Exposure-toxicity relationships for tipifarnib in cancer patients: *J.J. Perez-Ruixo, W. Chen, S. Zhang, S. Hayes & A. Chow*

Short reports

233 Perception of risk of adverse drug reactions by medical students: influence of a 1 year pharmacological course: *G. Durrieu, C. Hurault, V. Bongard, C. Damase-Michel & J.L. Montastruc*

237 Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity: *N. Magné, M.-C. Etienne-Grimaldi, L. Cals, N. Renée, J.-L. Formento, M. Francoual & G. Milano*

241 Age dependent systemic exposure to inhaled salbutamol: *K. Bønnelykke, J.J. Jespersen & H. Bisgaard*

Letters to the editors

245 Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients: *P.K. Subbanna, C.G. Prasanna & B.K. Gunale*

246 Safety of amlodipine use in patients with acute intermittent porphyria: *H. Cinemre, U. Korkmaz, A. Alcelik, E. Onder & A. Gungor*

Book review

248 Ethnopharmacology of Medicinal Plants: Asia and the Pacific: *Edited by C. Wiart; reviewed by P. Houghton*

Volume 64, Number 3, September 2007

Editors' view

249 Should we tolerate tolerability as an objective in early drug development?: *A. Cohen*

Editors' report

253 Editors' Report for 2006: *J.K. Aronson, A. Cohen, J.M. Ritter, E.J. Begg, L.D. Lewis, M.S. Chachter*

Review

255 Use of statins and risk of haematological malignancies: a meta-analysis of six randomized clinical trials and eight observational studies: *S. Bonovas, K. Filioussi, A. Tsantes & N.M. Sitaras*

Commentary

263 Development of oral anticoagulants: *Q. Ma*

Pharmacokinetics & pharmacodynamics

266 Randomized exposure-controlled trials; impact of randomization and analysis strategies: *K.E. Karlsson, A. Grahnén, M.O. Karlsson & E.N. Jonsson*

278 Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response: *D.R. Mould, A. Baumann, J. Kuhlmann, M.J. Keating, S. Weitman, P. Hillmen, L.R. Brettman, S. Reif & P.L. Bonate*

292 The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects: *J. Stangier, K. Rathgen, H. Stähle, D. Gansser & W. Roth*

304 Single and multiple ascending dose studies of a novel tissue-selective oestrogen receptor modulator, CHF 4227, in healthy postmenopausal women: *M. Civelli, A.P.M. Preti, V. Cenacchi, I. Rondelli, D. Guastalla, A. Tarral, P. Dostert, Y. Guillevic & M.-C. Homery*

Pharmacokinetics

317 Effect of renal impairment on the pharmacokinetics of exenatide: *H. Linnebjerg, P.A. Kothare, S. Park, K. Mace, S. Reddy, M. Mitchell & R. Lins*

328 Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size: *J.E. Esposito-Festen, P. Zanen, H.A.W.M. Tiddens & J.-W.J. Lammers*

335 A pharmacokinetic model for L-carnitine in patients receiving haemodialysis: *G. Fornasini, R.N. Upton & A.M. Evans*

Pharmacogenetics

346 *SLCO1B1* 521T→C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients: *W. Zhang, B.-L. Chen, V. Ozdemir, Y.-J. He, G. Zhou, D.D. Peng, S. Deng, Q.-Y. Xie, W. Xie, L.-Y. Xu, L.-C. Wang, L. Fan, A. Wang & H.-H. Zhou*

353 Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients: *C. Solas, N. Simon, M.-P. Drogoul, S. Quaranta, V. Frixon-Marin, V. Bourgarel-Rey, C. Brunet, J.-A. Gastaut, A. Durand, B. Lacarelle & I. Poizot-Martin*

Therapeutics

363 Foundation year 1 doctors and clinical pharmacology and therapeutics teaching. A retrospective view in light of experience: *M. Tobaiqy, J. McLay & S. Ross*

373 Consumption of herbal remedies and dietary supplements amongst patients hospitalized in medical wards: *L.H. Goldstein, M. Elias, G. Ron-Avraham, B.Z. Biniaurishvili, M. Madjar, I. Kamargash, R. Braunstein, M. Berkovitch & A. Golik*

Short reports

381 Primary care prescribing patterns in Ireland after the publication of large hypertension trials: *Z. Kabir, J. Feely & K. Bennett*

386 Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole: *M.B. Sostek, Y. Chen & T. Andersson*

391 *CYP2B6* 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment: *R.K. Mehlotra, M.J. Bockarie & P.A. Zimmerman*

Letters to the editors

396 Homeopathy is safe and does not lack positive evidence in clinical trials: *R.T. Mathie & P. Fisher*

397 Scottish GPs use of homeopathy: *R. Leckridge*

398 Authors' response: Homeopathy is safe and does not lack positive evidence in clinical trials/Scottish GPs use of Homeopathy: *S. Ross, C. Simpson & J. McLay*

Book review

400 Heart Rate Slowing by I_f Current Inhibition: *Edited by D. Noble & M. Tendera; reviewed by D. Noble*

401 Erratum

Volume 64, Number 4, October 2007

Editors' view

403 Plagiarism – please don't copy: *J.K. Aronson*

Review

406 The contribution of observational studies to the knowledge of drug effectiveness in heart failure: *D. Dobre, D.J. van Veldhuisen, M.J.L. deJongste, E. van Sonderen, O.H. Klungel, R. Sanderman, A.V. Ranchor & F.M. Haaijer-Ruskamp*

Commentary

415 A re-evaluation of kava (*Piper methysticum*): *E. Ernst*

418 The safety of kava – a regulatory perspective: *W.N. Richardson & L. Henderson*

Pharmacodynamics

421 Repeated cycles of electrical stimulation decrease vasoconstriction and axon-reflex vasodilation to noradrenaline in the human forearm: *P.D. Drummond*

428 Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old: *A. Berges, S. Laporte, M. Epinat, P. Zufferey, E. Alamartine, B. Tranchand, H. Decousus, & P. Mismetti for the PROPHRE.75 study group*

Pharmacokinetics

439 Plasma concentrations of fluticasone propionate and budesonide following inhalation: effect of induced bronchoconstriction: *K.J. Mortimer, A.E. Tattersfield, Y. Tang, K. Wu, S. Lewis, G. Hochhaus & T.W. Harrison*

445 Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele: *Y.M. Cui, C.H. Teng, A.X. Pan, E. Yuen, K.P. Yeo, Y. Zhou, X. Zhao, A.J. Long, M.E. Bangs & S.D. Wise*

Durg metabolism

450 Identification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide elimination: *D.J. Elliot, Suharjono, B.C. Lewis, E.M.J. Gillam, D.J. Birkett, A.S. Gross & J.O. Miners*

458 Limited influence of *UGT1A1*28* and no effect of *UGT2B7*2* polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes: *V.C. Peterkin, J.N. Bauman, T.C. Goosen, L. Menning, M.Z. Man, J.D. Paulauskis, J.A. Williams & S.P. Myrand*

Drug interaction

469 Effects of *Schisandra sphenanthera* extract on the pharmacokinetics of tacrolimus in healthy volunteers: *H.-W. Xin, X.-C. Wu, Q. Li, A.-R. Yu, M. Zhu, Y. Shen, D. Su & L. Xiong*

Pharmacoepidemiology

476 Switching statins in Norway after new reimbursement policy – a nationwide prescription study: *S. Sakshaug, K. Furu, Ø. Karlstad, M. Rønning & S. Skurtveit*

482 Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions: *Y. Arimone, G. Miremont-Salamé, F. Haramburu, M. Molimard, N. Moore, A. Fourrier-Réglat & B. Bégaud*

489 Detecting signals of drug–drug interactions in a spontaneous reports database: *B.T. Thakrar, S.B. Grundschober & L. Doessegger*

Drug safety

496 Risk of congenital anomalies in pregnant users of statin drugs: *B. Ofori, E. Rey & A. Bérard*

510 Ergotamine treatment during pregnancy and a higher rate of low birthweight and preterm birth: *F. Bánhidy, N. Ács, E. Puhó & A.E. Czeizel*

Therapeutics

517 Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin: *C.M. Forrest, G.M. Mackay, N. Stoy, T.W. Stone & L.G. Darlington*

527 Impact of Vietnamese written and verbal medicine information on Vietnamese-speaking Australians' knowledge and satisfaction: *A. Mai & P. Aslani*

536 What therapies have replaced rofecoxib in Ireland?: *M. Teeling, H. O'Connor, J. Feely & K. Bennett*

Short reports

542 Clindamycin and taste disorders: *M.C.H. de Groot & E.P. van Puijenbroek*

546 When a placebo is not a 'placebo': a placebo effect on postprandial glycaemia: *J.L. Sievenpiper, A. Ezatagha, A. Dascalu & V. Vuksan*
550 Ischaemic complications of Glypressin in liver disease: a case series: *F. Donnellan, G. Cullen, J.E. Hegarty & P.A. McCormick*

Letters to the Editors
553 Severe local vancomycin induced skin necrosis: *D.W.M. Hoelen, D.H.T. Tjan, R. van Vugt, Y.G. van der Meer & A.R.H. van Zanten*
555 Efficacy of phenylephrine: *P.J. Desjardins & R.G. Berlin*
557 Efficacy of phenylephrine: *R. Eccles*
558 Risperidone-induced recurrent giant urticaria: *B. Mishra, S. Saddichha, R. Kumar & S. Akhtar*
560 Delayed bezafibrate-induced angio-oedema in a 68-year-old man: *M. Frendo, R. Theuma & S. Fava*

Book review
562 Burroughs Wellcome & Co. Knowledge, Trust, Profit and the Transformation of the British Pharmaceutical Industry, 1880–1940: *Edited by R. Church & T. Tansey; reviewed by A. Cohen*

Volume 64, Number 5, November 2007

Editors' view
563 Old drugs – new uses: *J.K. Aronson*

Review Article
566 Thioridazine: resurrection as an antimicrobial agent?: *H.K.R. Thanacoody*

Commentary
575 Stroke prevention in atrial fibrillation – things can only get better: *G.Y.H. Lip & T. Watson*
578 Commentary on Dartois *et al.* – model building in population PK–PD analyses. A 2002–2004 literature survey: *G. (Colin) Pillai & J.-L. Steimer*

Pharmacodynamics
580 Reproducibility of the capsaicin-induced dermal blood flow response as assessed by laser Doppler perfusion imaging: *B.J. Van der Schueren, J.N. de Hoon, F.H. Vanmolkot, A. Van Hecken, M. Depre, S.A. Kane, I. De Lepeleire & S.R. Sinclair*
591 Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers: *E.R. Samuels, R.H. Hou, R.W. Langley, E. Szabadi & C.M. Bradshaw*

Pharmacokinetics and pharmacodynamics
603 Overview of model-building strategies in population PK/PD analyses: 2002–2004 literature survey: *C. Dartois, K. Brendel, E. Comets, C.M. Laffont, C. Laveille, B. Tranchand, F. Mentré, A. Lemenuel-Diot & P. Girard*
613 Relationship between 5-fluorouracil exposure and outcome in patients receiving continuous venous infusion with or without concomitant radiotherapy: *M. Beneton, S. Chapet, H. Blasco, B. Giraudeau, M. Boisdron-Celle, R. Deporte-Fety, F. Denis, B. Narcisso, G. Calais & C. Le Guellec*
622 Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic–pharmacodynamic study: *M. Joerger, A.D.R. Huitema, M.T. Huizing, P.H.B. Willemse, A. de Graeff, H. Rosing, J.H.M. Schellens, J.H. Beijnen & J.B. Vermorken*
634 Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples: *D. Hirt, S. Urien, V. Jullien, G. Firtion, H. Chappuy, E. Rey, G. Pons, L. Mandelbrot & J.-M. Treluyer*

Pharmacogenetics
645 The effect of ABCG2 V12M, Q141K and Q126X, known functional variants *in vitro*, on the disposition of lamivudine: *H.-S. Kim, Y.E. Sunwoo, J.Y. Ryu, H.-J. Kang, H.-E. Jung, I.-S. Song, E.-Y. Kim, J.-C. Shim, J.-H. Shon & J.-G. Shin*

Drug interactions
655 Pharmacokinetic interaction between TMC114/ritonavir and tenofovir disoproxil fumarate in healthy volunteers: *R.M.W. Hoetelmans, K. Mariën, M. De Pauw, A. Hill, M. Peeters, V. Sekar, P. De Doncker, B. Woodfall & E. Lefebvre*

Drug safety
662 Diclofenac and acute myocardial infarction in patients with no major risk factors: *S.S. Jick, J.A. Kaye & H. Jick*
668 Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias: *S. Thunell, E. Pomp & A. Brun*

Therapeutics
680 Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution: *P.D. Gumbs, W.M.M. Verschuren, P.C. Souverein, A.K. Mantel-Teeuwisse, G.A. de Wit, A. de Boer & O.H. Klungel*
686 Effective dose of nefopam in 80% of patients (ED_{80}): a study using the continual reassessment method: *H. Beloeil, M. Eurin, A. Thévenin, D. Benhamou & J.-X. Mazoit*

Short reports
694 Cardiovascular toxicity due to metoprolol poisoning in a patient with coronary artery disease: *P. Unverir, H. Topacoglu, S. Bozkurt & F. Kaynak*
698 Pharmacokinetic/pharmacodynamic evaluation of urinary cortisol suppression after inhalation of fluticasone propionate and mometasone furoate: *Z.R. Tayab, T.C. Fardon, D.K.C. Lee, K. Haggart, L.C. McFarlane, B.J. Lipworth & G. Hochhaus*
706 National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing: *A. Mahmud, K. Bennett, I. Okechukwu & J. Feely*

Letters to the Editors
710 Concordance is not synonymous with compliance or adherence: *J.S. Bell, M.S. Airaksinen, A. Lyles, T.F. Chen & P. Aslani*
711 Time to abandon the term 'patient concordance': *J.K. Aronson*
714 Polonium-210 in news: an allegory of a misappropriated science: *N.K. Singh*
715 Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report: *S. Sahoo, B. Mishra & S. Akhtar*
717 Prolonged oro-facial dystonia in a 58 year old female following therapy with bupropion and St John's Wort: *J.C. Milton & A. Abdulla*

Volume 64, Number 6, December 2007

Editors' view

719 Drugs and the kidney: more than a question of dose: *D.G. Waller*

Short Review

722 Choice of first antihypertensive – are existing guidelines ignored?: *I. Okechukwu, A. Mahmud, K. Bennett & J. Feely*

Pharmacokinetics in renal insufficiency and dialysis

726 Multiple-dose pharmacokinetics of peginterferon alfa-2b in patients with renal insufficiency: *S.K. Gupta, S.K. Swan, T. Marbury, W. Smith, S. Schwartz, K. Kolz & D.L. Cutler*

733 The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment: *N. Dhaun, V. Melville, W. Kramer, F. Stavros, T. Coyne, S. Swan, J. Goddard & D.J. Webb*

738 Pharmacokinetics of lamivudine in subjects receiving peritoneal dialysis in end-stage renal failure: *A. Asari, H. Iles-Smith, Y.-C. Chen, O.J. Naderer, M.A. Johnson, G.J. Yuen, V. Otto, J.A. Dunn & R. Gokal*

745 The influence of continuous venovenous haemodialysis on the pharmacokinetics of multiple oral moxifloxacin administration to patients with severe renal dysfunction: *H. Stass, S. Bührmann, A. Mitchell, D. Kubitza, J.-G. Möller, A. Kribben, R.R. Wenzel & R.F. Schäfers*

Pharmacokinetics in renal transplantation

750 Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients: *M. Antignac, B. Barrou, R. Farinotti, P. Lechat & S. Urien*

758 Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients: *M.D. Pescovitz, F. Vincenti, M. Hart, L. Melton, J. Whelchel, S. Mulgaonkar, D. McKay, M. Leung, E. Calleja & M.R. Bouw*

772 Developmental pharmacokinetics of ciclosporin – a population pharmacokinetic study in paediatric renal transplant candidates: *S. Fanta, S. Jönsson, J.T. Backman, M.O. Karlsson & K. Hoppu*

Pharmacodynamic effects

785 Effect of dronedarone on renal function in healthy subjects: *Y. Tschuppert, T. Buclin, L.E. Rothuizen, L.A. Decosterd, J. Galleyrand, C. Gaud & J. Biollaz*

792 Add-on therapy with doxazosin in patients with hypertension influences arterial stiffness and albuterol-mediated arterial vasodilation: *A. Wykretowicz, P. Guzik, T. Krauze, K. Adamska, A. Milewska & H. Wysocki*

796 Absence of tolerance and toxicity to high-dose continuous intravenous furosemide in haemodynamically unstable infants after cardiac surgery: *M.M.J. van der Vorst, J.E. Kist-van Holthe, J. den Hartigh, A.J. van der Heijden, A.F. Cohen & J. Burggraaf*

804 Sublingual administration of furosemide: new application of an old drug: *L. Haegeli, H.P.B.-L. Rocca, M. Wenk, M. Pfisterer, J. Drewe & S. Krähenbühl*

Adverse effects

810 The effect of screening for cardio-renal risk factors on drug use in the general population: *J. Atthobari, R.T. Gansevoort, S.T. Visser, P.E. de Jong & L.T.W. de Jong-van den Berg*

819 Proton pump inhibitor-induced acute interstitial nephritis: *L. Härmark, H.E. van der Wiel, M.C.H. de Groot & A.C. van Grootheest*

824 Effect of acute paracetamol overdose on changes in serum and urine electrolytes: *N. Pakravan, D.N. Bateman & J. Goddard*

Letter to the Editors

833 Carbamazepine-induced urinary retention: *H. Hmouda, C.B. Salem, M. Grira, R. Slim & K. Bouraoui*

835 Author Index

842 Subject Index

845 Reviewers for 2007

v Volume Contents